Skip to main content

Advertisement

Table 2 Univariate analyses of factors by cox regression model associated with recurrence-free survival (RFS) in test and validation cohort (*, P < 0.05; **, P < 0.01)

From: Evaluation of high-risk clinicopathological indicators in gastrointestinal stromal tumors for prognosis and imatinib treatment outcome

  Test cohort   Validation cohort  
Variable RFS hazard ratio (95% Cl) Pvalue RFS hazard ratio (95% Cl) Pvalue
Age (≤50, > 50) 0.463 (0.178-1.206) 0.115 3.673 (1.126-11.983) 0.031*
Gender (male, female) 0.594 (0.237-1.489) 0.266 0.342 (0.161-0.728) 0.005**
Tumor site (stomach, no stomach) 9.629 (2.820-32.879) <0.001** 1.760 (0.900-3.440) 0.098
Tumor size (≤10, > 10 cm) 8.732 (3.604-21.154) <0.001** 5.392 (2.787-10.430) <0.001**
Mitosis count (≤10, > 10/50 HPF) 13.459 (5.470-33.115) <0.001** 8.462 (4.335-16.519) <0.001**
Serosal invasion (Yes, No) 20.531 (8.170-51.596) <0.001** 7.706 (3.938-15.081) <0.001**